Is alcohol beneficial or harmful for cardioprotection?

Genes and Nutrition

Volumn 5, Issue 2, 2010, Pages 111-120

  Lakshman, Raj ^a,b   Garige, Mamatha ^b   Gong, Maokai ^b   Leckey, Leslie ^a   Varatharajalu, Ravi ^b   Zakhari, Samir ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Coronary artery disease; Ethanol; Homocysteine thiolactonase; Paraoxonase; Quercetin; Sterol regulatory element binding protein

Indexed keywords

ALCOHOL; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; CLUSTERIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; QUERCETIN; RESVERATROL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ALCOHOL CONSUMPTION; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIET THERAPY; DRINKING BEHAVIOR; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENOTYPE; HEART DISEASE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; NONHUMAN; PROTEIN DEFECT; PROTEIN FUNCTION; REVIEW; UPREGULATION; WINE;

ANIMALIA; RATTUS;

EID: 77955982697     PISSN: 15558932     EISSN: 18653499     Source Type: Journal    
DOI: 10.1007/s12263-009-0161-2     Document Type: Review

References (119)

1. Gunzerath L, Faden V, Zakhari S, Warren K (2004) National Institutes on alcohol abuse and alcoholism report on moderate drinking. Alcohol Clin Exp Res 28(6):829-847
2. O'Keefe JH, Bybee KA, Lavie CJ (2007) Alcohol and cardiovascular health. J Am Col Cardiol 50:1009-1014
3. Parthasarathy S, Rankin SM (1992) Role of oxidized LDL in atherogenesis. Prog Lipid Res 31:127-143
4. Chisolm GM, Steinberg D (2000) The oxidative modification hypothesis of atherogenesis: an overview. Free Rad Biol Med 28:1815-1826
5. Lakshman MR, Reda D, Materson BJ (1996) Plasma lipid and lipoprotein profiles in hypertensive black vs white men. Am J Cardiol 78:1236-1241
6. Belfrage P, Berg B, Hagerstrand I, Nilsson-Ehle P (1977) Alterations of lipid metabolism in healthy volunteers during long-term ethanol intake. Eur J Clin Invest 7(2):127-131
7. Hulley SB, Cohen R, Widdowson G (1977) Plasma high density lipoprotein cholesterol level- influence of risk factor intervention. J Am Med Assoc 238(21):2269-2271
8. Jacqueson A, Richard JL, Ducimetiere P, Warnet JM, Claude JR (1983) HDL cholesterol and alcohol consumption in a French male population. Atherosclerosis 48(2):131-138
9. Klatsky AL, Freidman GD, Siegelaub AB (1974) Alcohol consumption before myocardial infarction. Ann Intern Med 81:294-301
10. Barboriak JJ, Rimm AA, Anderson AJ, Schmidhoffer M, Tristani FE (1977) Coronary artery occlusion and alcohol intake. Br Heart J 39:289-293
11. Masarei JRL, Puddey IL, Rouse WJ (1986) Effects of alcohol consumption on serum lipoprotein-lipid and apolipoprotein concentrations. Atherosclerosis 60:79-87
12. Haskell WL, Camargo C Jr, Williams PT (1984) Effect of cessation and resumption of moderate alcohol intake on serum HDL subfractions. N Engl J Med 310:805-810
13. Hartung GH, Foreyt JP, Mitchell RE, Mitchell JG, Reeves RS, Gotto AM (1983) Effect of alcohol intake on HDL cholesterol levels in runners and inactive men. JAMA 249:747-750
14. Cushman P, Barboriak J, Kalbfleisch J (1986) Alcohol: high density lipoproteins, apolipoproteins. Alcohol Clin Exp Res 10(2):154-157
15. Lieber CS (1984) To drink "moderately" or not to drink? N Engl J Med 310:846-848
16. Kagan A, Yano K, Rhoads GC et al (1981) Alcohol and cardiovascular disease: the Hawaiian experience. Circulation 64(3 Pt 2):III 27-III 31
17. Lakshman MR, Chirtel SC, Chamber LC (1988) Roles of x3- fatty acids and ethanol on the regulation of plasma and liver lipids and apo A-I and E in rats. J Nutr 118:1299-1303
18. Lin RC, Lumeng L, Phelps VL (1989) Serum HDL particles of alcohol fed rats are deficient in apolipoprotein E. Hepatology 9:307-313
19. Marmillot P, Rao MN, Liu Q-H, Chirtel SJ, Lakshman MR (2000) Effect of dietary x3-fatty acids & ethanol consumption on RCT in rats. Metabolism 49:508-512
20. Rao MN, Marmillot P, Seeff LB, Strader DB, Lakshman MR (2000) HDL from human alcoholics exhibit impaired RCT function. Metabolism 49:1406-1410
21. Croft KD, Puddey IB, Rakic V, Abu-Amsha R et al (1996) Oxidative susceptibility of LDL-influence of regular alcohol use. Alcohol Clin Exp Res 20(6):980-984
22. Kervinen K, Savolainen MJ, Kesaniemi YA (1991) LDL derivatization by acetaldehyde affects lysine residues & B/E receptor binding affinity. Alcohol Clin Exp Res 15(6):1050-1055
23. Kesaniemi YA, Kervinen K, Meittinen TA (1987) Acetaldehyde modification of low density lipoprotein accelerates its catabolism in man. Eur J Clin Invest 17:29-36
24. Rao MN, Marmillot P, Palmer DA, Seeff LJ, Strader DB, Lakshman MR (2003) Light, but not heavy alcohol drinking stimulates paraoxonase by up regulating liver PON mRNA in both rats and humans. Metabolism 52:1287-1294
25. Ohnishi K, Lieber CS (1977) Reconstitution of microsomal ethanol-oxidizing system. J Biol Chem 252:7124-7131
26. DiLuzio NR (1964) Prevention of the acute ethanol-induced fatty liver by the simultaneous administration of antioxidants. Life Sci 3:113-118
27. DiLuzio NR, Costales F (1965) Inhibition of ethanol and carbon tetrachloride induced fatty liver by antioxidants. Exp Mol Pathol 4:141-154
28. DiLuzio NR, Kalish GH (1966) Enhanced peroxidation of lipid in the pathogenesis ethanol induced liver injury. Gastroenterology 50:392-396
29. Cederbaum AJ (1987) Microsomal generation of hydroxyl radicals: its role in microsomal ethanol oxidizing system (MEOS) activity and requirement for iron. Ann N Y Acad Sci 492:35-49
30. Ahmad FF, Cowan DL, Sun AY (1989) Spin trapping and lipid peroxidation. In: Sun GY, Wood WG, Sun AY (eds) Molecular mechanisms of alcohol. Humana Press, Clifton, pp 257-278
31. Reinke LA, McCay PB (1991) Alcohol and free radicals. In: Watson RR (ed) Liver pathology and alcohol, vol 99. Humana Press, Clifton, pp 133-168
32. Esterbauer H, Jurgens G, Quenhenberger O (1987) Autoxidation of human LDL. J Lip Res 28:495-509
33. Esterbauer H, Striegl G, Puhl H, Rotheneder M (1989) Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6:67-75
34. Klatsky AL (1982) Alcohol and the cardiovascular system. Ann Rev Nutr 2:51-71
35. Regan TJ (1984) Alcoholic cardiomyopathy. Prog Cardiovasc Dis 27:141-152
36. Urbano-Marquez A, Estrich R, Navarro-Lopez F (1989) The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 320:409-415
37. Klatsky AL (1990) In hypertension: pathophysiology, diagnosis and management. Raven Press, New York, pp 277-294
38. Donahue RP, Abbott RD, Reed DW et al (1986) Alcohol and hemorrhagic stroke. The Honolulu heart program. JAMA 255:2311-2314
39. Ettinger PO, Wu CF, De La Cruz C et al (1978) Arrhythmias and the "Holiday Heart": alcohol-associated cardiac rhythm disorders. Am Heart J 95:555-562
40. Stampfer MJ, Colditz GA, Willet WC (1988) A study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Ed 319:267-273
41. Klatsky AL, Armstrong MA, Friedman GD (1986) Relations of alcoholic beverage use to subsequent coronary artery disease hospitalization. Am J Cardiol 58:710-714
42. Yano K, Rhoads GG, Kagan A (1977) Coffee, alcohol and risk of coronary heart disease among Japanese men living in Hawaii. N Engl J Med 297:405-409
43. Scragg R, Stewart A, Jackson R (1987) Alcohol and exercise in myocardial infarction and sudden coronary death in men and women. Am J Epidemiol 126:77-85
44. Castelli WP, Doyle JT, Gordon T et al (1977) Alcohol and blood lipids. The cooperative lipoprotein phenotyping study. Lancet 2:153-155
45. Cauley JA, Kuller LH, LaPorte RE (1987) Studies on the association between alcohol and HDL cholesterol: possible benefits and risks. Adv Alcohol Subst Abuse 6:53-67
46. Moore RD, Smith CR, Kwiterovich PO, Pearson TA (1988) Effect of low-dose alcohol use versus abstention on apolipoproteins A-I and B. Am J Med 84:884-896
47. Lucas DL, Brown RA, Wassef M, Giles TD (2005) Alcohol and the cardiovascular system. J Am Coll Cardiol 45:1916-1924
48. Femia R, Natali A, L'Abbate A, Ferrannini E (2006) Coronary atherosclerosis and alcohol consumption: angiographic and mortality data. Arter Thromb Vasc Biol 26:1607-1612
49. Vliegenthart R, Oei HHS, van den Elzen APM et al (2004) Alcohol consumption and coronary calcification in a general population. Arch Intern Med 164:2355-2360
50. Schminke U, Luedemann J, Berger K et al (2005) Association between alcohol consumption and subclinical carotid atherosclerosis: the Study of Health in Pomerania. Stroke 36:1746-1752
51. Anonymous (1988) Alcohol and mortality: myth of U-shaped curve. Lancet 2:1292-1293
52. Kabagambe EK, Baylin A, Ruiz-Narvaez E, Rimm EB, Campos H (2005) Alcohol intake, drinking patterns, and risk of nonfatal acute myocardial infarction in Costa Rica. Am J Clin Nutr 82:1336-1345
53. Mukamal KJ, Jensen MK, Grønbæk M et al (2005) Drinking frequency, mediating biomarkers, and risk of myocardial infarction in women and men. Circulation 112:1406-1413
54. Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (The INTERHEART study): case-control study. Lancet 364:937-952
55. Mukamal KJ, Chiuve SE, Rimm EB (2006) Alcohol consumption and risk for coronary heart disease in men with healthy lifestyles. Arch Intern Med 166:2145-2150
56. Beulens JW, Rimm EB, Ascherio A, Spiegelman D, Hendriks HF, Mukamal KJ (2007) Alcohol consumption and risk for coronary heart disease among men with hypertension. Ann Intern Med 146:10-19
57. Djoussé L, Gaziano JM (2007) Alcohol consumption and risk of heart failure in the Physicians' Health Study I. Circulation 115:34-39
58. Beilin LJ, Puddey IB (2006) Alcohol and hypertension: an update. Hypertension 47:1035-1038
59. Mukamal KJ, Conigrave KM, Mittleman MA et al (2003) Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 348:109-118
60. Veenstra J, Ockhuizen T, van de Pol H, Wedel M, Schaafsma G (1990) Effects of a moderate dose on blood lipids and lipoproteins postprandially and in the fasting state. Alcohol Alcohol 25(4):371-377
61. Rehm J, Sempos CT, Trevisan M (2003) Alcohol and cardiovascular disease-more than one paradox to consider average volume of alcohol consumption, patterns of drinking and risk of coronary heart disease-a review. J Cardiovasc Risk 10:15-20
62. Mukamal KJ, Maclure M, Muller JE, Mittleman MA (2005) Binge drinking and mortality after acute myocardial infarction. Circulation 112:3839-3845
63. Naimi TS, Brewer RD, Mokdad A, Denny C, Serdula MK, Marks JS (2003) Binge drinking among US adults. JAMA 289:70-75
64. Malyutina S, Bobak M, Kurilovitch S et al (2002) Relation between heavy and binge drinking and all-cause and CV mortality in Novosibirsk, Russia: a prospective cohort study. Lancet 360:1448-1454
65. DiCastelnuovo A, Castanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G (2006) Alcohol dosing and total mortality in men and women. Arch Intern Med 166:2437-2445
66. Bantle JP et al (2006) Nutrition recommendations and interventions for diabetes-2006: a position statement of the American Diabetes Association. Diabetes Care 29:2140-2157
67. Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Campbell LV (2003) Moderate alcohol consumption, estrogen replacement therapy, and physical activity are associated with increased insulin sensitivity. Diabetes Care 26:2734-2740
68. Rimm EB, Giovannucci EL, Willett WC et al (1991) Prospective study of alcohol consumption and risk of coronary artery disease in men. Lancet 338(8765):464-468
69. Hein HO, Suadicani P, Gyntelberg F (1996) Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: six year follow up in the Copenhagen male study. BMJ 312(7033):736-741
70. Lazarus NB, Kaplan GA, Cohen RD, Leu DJ (1991) Change in alcohol consumption and risk of death from all causes & ischaemic heart disease. BMJ 303(6802):553-556
71. Friedman LA, Kimball AW (1986) Coronary heart disease mortality and alcohol consumption in Framingham. Am J Epidemiol 124(3):481-489
72. Corder R, Mullent W, Khan NQ et al (2006) Red wine procyanidins and vascular health. Nature 444:566
73. Hertog MG, Feskens EJM, Hollman P (1993) Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342(8878):1007-1011
74. Knekt P, Jarvinen R, Reunanen A, Maatela J (1996) Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 312(7029):478-481
75. Klurfeld DM, Kritchevsky D (1981) Differential effects of alcoholic beverages on experimental atherosclerosis in rabbits. Exp Mol Pathol 34(1):62-71
76. Rimm EB, Yjatsky A, Grobbee D, Stampfer MJ (1996) Review of moderate alcohol consumption and reduced risk of coronary heart disease. BMJ 312(7033):731-736
77. Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary artery disease. Lancet 339(8808):1523-1526
78. St Leger AS, Cochrane AL, Moore F (1979) Factors associated with cardiac mortality in developed countries with reference to the consumption of wine. Lancet 1(8124):1017-1020
79. Aviram M, Rosenblat M, Billeke S, La Du B (1999) Human serum PON is inactivated by oxidized LDL and preserved by antioxidants. Free Rad Biol Med 26:892-904
80. Fuhrman B, Aviram M (2002) Preservation of paraoxonase activity by wine flavonoids. Ann N Y Acad Sci 957:321-324
81. Vigna GB, Costantini F, Aldini G et al (2003) Effect of grape seed extract on low-density lipoprotein susceptibility to oxidation in heavy smokers. Metabolism 52:1250-1257
82. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996) Human serum paraoxonase/arylesterase (PON1) is one member of a multigene family. Genomics 33:498-507
83. La Du BN (1992) Human serum paraoxonase/arylesterase. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon Press, New York, pp 51-91
84. Chemnitius JM, Losch H, Losch K, Zech R (1983) Organophosphate detoxicating hydrolases in different vertebrate species. Comp Biochem Physiol C 76(1):85-93
85. Saha N, Roy AC, Teo SH, Tay JS, Ratnam SS (1991) Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 40:277-282
86. Mackness MI, Arrol S, Abbott CA, Durrington PN (1993) Is paraoxanase related to atherosclerosis. Chem Biol Interac 87:161-171
87. Mackness MI, Walker CH, Carlson LA (1987) Low A-esterase activity in serum of patients with fish-eye disease. Clin Chem 33:587-588
88. Mackness MI (1989) In: Reiner E, Aldridge WN, Hoskins FCG (eds) Enzymes hydrolysing organophosphorus compounds, pp 202-213
89. Jaichander P, Selvarajan K, Garelnabi M, Parthasartahy S (2008) Induction of PON1 and apolipoprotein A-1 gene expression by asprin. J Lipid Res 49:2142-2148
90. Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152-154
91. Ng CJ, Wadleigh DJ, Gangopadhyay A (2001) Paraoxonase 2 is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444-44449
92. Draganov DL, Stetson PL, Watson CE, Billecke SS, La Du BN (2000) Rabbit serum PON3 is a HDL associated lactonase and protects LDL against oxidation. J Biol Chem 275:33435-33442
93. Reddy ST, Wadleigh DJ, Grijalva V (2001) Human PON3 is a HDL enzyme with biological activity similar to PON1 but not regulated by oxidized lipids. Arter Throm Vasc Biol 21:542-547
94. Navab M, Hama-Levy S, Van Lenten BJ et al (1997) Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 99:2005-2019
95. Aviram M, Rosenbalt M, Bisgaier CL, Newton RS, Primo- Parmo SL, La Du BN (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101:1581-1590
96. Shih DM, Gu L, Xia YR et al (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287
97. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M (2003) Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107:2775-2779
98. Aviram M, Rosenblat M (2004) Paraoxonase 1, 2, 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 37:1304-1316
99. Jakubowski H (2000) Calcium-dependent human serum homocysteine thiolactone hydrolase. J Biol Chem 275:3957-3962
100. Sierksma A, van der Gaag MS, van Tol A, James RW, Hendriks HF (2002) Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin Exp Res 26(9):1430-1435
101. Lakshman MR, Gottipati CS, Narasimhan SJ, Munoz J, Marmillot P, Nylon ES (2006) Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism 55:1201-1206
102. Jakubowski H (2007) The molecular basis of homocysteine thiolactone-mediated vascular disease. Clin Chem Lab Med 45:704-1716
103. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125-1131
104. Deakin S, Leviev I, Guernier S, James RW (2003) Simvastatin modulates expression of the PON1 gene: a role for SREBP2. Arter Thromb Biol 23:2083-2089
105. Gouedard C, Koum-Besson N, Barouki R, Morel Y (2003) Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofirate and statins. Mol Pharmacol 63(4):945-956
106. Gouedard C, Barouki R, Morel Y (2004) Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol 24(12):5209-5222
107. Osaki F, Ikeda Y, Suehiro T, Ota K, Tsuzura S, Arii K, Kumon Y, Hashimoto K (2004) Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis 176(2):279-287
108. Rozenberg O, Shih DM, Aviram M (2003) Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2- like activity and lysophosphatidylcholine formation. Arter Thromb Vasc Biol 23(3):461-467
109. Marmillot P, Rao MN, Liu QH, Chirtel SJ, Lakshman MR (2000) Effect of dietary omega-3 fatty acids and chronic ethanol consumption on reverse cholesterol transport in rats. Metabolism 49(4):508-512
110. Rosenblat M, Vaya J, Shih DM, Aviram M (2005) Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179(1):69-77
111. Rozenberg O, Shih DM, Aviram M (2005) Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181(1):9-18
112. van Tol AA, Hendriks HFJB (2001) Moderate alcohol consumption: effects on lipids and cardiovascular disease risk. Curr Opin Lipidol 12:19-23
113. Agarwal DP (2002) Cardioprotective effects of light-moderate consumption of alcohol: a review of putative mechanisms. Alcohol Alcohol 37:409
114. van der Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, Hendriks HF (1999) Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomized intervention study in middle-aged men. Atherosclerosis 147:405
115. Prakash M, Shetty JK, Tripathy S, Verma M (2007) Letter to the editor: serum paraoxonase in alcohol abusers associated with alcoholic liver disease. Clin Chim Acta 378:232-234
116. Gong M, Garige M, Varatharajalu R, Marmillot P, Gottipatti C, Leckey LC (2009) Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation. Biochem Biophys Res Commun 379:1001-1004
117. Penumathsa SV, Maulik N (2009) Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 87:275-286
118. Dudley JI, Lekli I, Mukherjee S, Das M, Bertelli AA, Das DK (2008) Does white wine qualify for French paradox? Comparison of the cardioprotective effects of red and white wines and their constituents: resveratrol, tyrosol, and hydroxytyrosol. J Agric Food Chem 56:9362-9373
119. Chan AY, Dolinsky VW, Soltys CM, Viollet B, Baksh S, Light PE, Dyck JRB (2008) Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 283(35):24194-24201